Toxicology | Musculoskeletal & Dermatologic Pharmacology | Musculoskeletal Pain & Analgesia | Drug Eruptions | General Pharmacology
Overview of the safety of diclofenac diethylamine 2.32% gel
Edward Huskisson, Hans-Georg Predel, Bruno Giannetti, C Milliet, Martina Hagen*
*Corresponding author: Martina Hagen
Novartis Consumer Health, Nyon, Switzerland
F1000Posters 2011, 2: 1573 (poster) [English]
Poster [313.63 KB]
7th Congress of the European Federation of IASP Chapters (EFIC) 2011, 21 - 24 Sep 2011, T369
Some patients report local skin reactions when using topical nonsteroidal anti-inflammatory drugs (1). Therefore, the drug-related adverse events reported at the application site in studies evaluating diclofenac diethylamine (DDEA) 2.32% topical gel were collated to give an overview of its local tolerability.
Topical treatment with DDEA 2.32% gel was well tolerated locally, even under occlusive conditions, with few drug-related local adverse effects that were mostly mild to moderate. The phototoxic potential with DDEA 2.32% gel was minimal.
C Milliet and Martina Hagen are employees of Novartis Consumer Health.
Novartis Consumer Health, Not known
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License